Home › Funds › Eversept Partners, LP › TVTX

Eversept Partners, LP position in TVTX

TRAVERE THERAPEUTICS INC · Health Care

Eversept Partners, LP reported holding 798,973 shares of TVTX (TRAVERE THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$45.4M, representing 2.37% of its reported portfolio and ranking #12 among its reported holdings. Eversept Partners, LP has disclosed TVTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)798.97K sh
Reported value held$45.39M
Portfolio Weight2.37%
First reportedQ1 2024
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Eversept Partners, LP's TVTX position evolved

Eversept Partners, LP first disclosed a stake in TVTX in Q1 2024 at 955,618 shares (US$7.4M). The position peaked in Q2 2026 at 798,973 shares, worth US$45.4M. Across 10 filings, Eversept Partners, LP increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 798,973 shares valued at US$45.4M — an increase of 256,363 shares quarter over quarter.. Notable position changes include a 66% increase in Q1 2025 (shares fell 17% over the following quarter), a 61% increase in Q2 2025 (shares rose 61% over the following quarter), a 54% trim in Q1 2026 (shares rose 91% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2024 955.62K $7.37M New
Q2 2024 1.09M $8.97M Add
Q3 2024 869.91K $12.17M Reduce
Q4 2024 490.30K $8.54M Reduce
Q1 2025 816.25K $14.63M Add
Q2 2025 1.32M $19.46M Add
Q3 2025 1.42M $33.87M Add
Q4 2025 1.17M $44.90M Reduce
Q1 2026 542.61K $16.12M Reduce
Q2 2026 798.97K $45.39M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TVTX and 13F data

TVTX (TRAVERE THERAPEUTICS INC) is a Health Care company. 56 other funds we track also report a position in TVTX — the largest reported positions include PERCEPTIVE ADVISORS LLC (US$213.2M), Rock Springs Capital Management LP (US$123.8M), Kynam Capital Management, LP (US$113.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TVTX

All TVTX fund holders →

FAQ

How long has Eversept Partners, LP held TVTX?

Eversept Partners, LP has disclosed TVTX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is Eversept Partners, LP's current position in TVTX?

As of Q2 2026, Eversept Partners, LP holds 798.97K shares of TVTX (TRAVERE THERAPEUTICS INC), valued at $45.39M, representing 2.37% of its reported portfolio and ranking #12.

Has Eversept Partners, LP been buying or selling TVTX?

In the latest 13F filing (Q2 2026), Eversept Partners, LP increased its position in TVTX. The position peaked in Q2 2026 at 798.97K shares.

Which other funds hold TVTX?

Other major institutional holders of TVTX include PERCEPTIVE ADVISORS LLC, Rock Springs Capital Management LP, Kynam Capital Management, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.